Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBT (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EBT for 10 consecutive years, with -$127.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 3.86% to -$127.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$571.0 million, a 0.71% decrease, with the full-year FY2025 number at -$571.0 million, down 0.71% from a year prior.
  • EBT was -$127.7 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$179.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$72.8 million in Q3 2021 to a low of -$238.8 million in Q3 2022.
  • A 5-year average of -$145.2 million and a median of -$142.8 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 574.02% in 2021, then skyrocketed 33.42% in 2023.
  • Ultragenyx Pharmaceutical's EBT stood at -$124.8 million in 2021, then dropped by 22.85% to -$153.3 million in 2022, then grew by 16.87% to -$127.4 million in 2023, then dropped by 4.23% to -$132.8 million in 2024, then increased by 3.86% to -$127.7 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's EBT are -$127.7 million (Q4 2025), -$179.5 million (Q3 2025), and -$114.0 million (Q2 2025).